Drug and Therapeutics Bulletin 2007;45:37-40; doi:10.1136/dtb.2007.45537
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Update on drugs for hyperactivity in childhood

Relevant BNF section: 4.4

In 2001, we concluded that methylphenidate or dexamfetamine can be useful adjunctive therapy for children with severe hyperactivity in whom non-drug approaches alone have been inadequate.1 Since then, {blacktriangledown}atomoxetine (pronounced a-toe-moks-e-teen; Strattera – Lilly) and three modified-release formulations of methylphenidate have been launched for attention deficit hyperactivity disorder (ADHD). Here we reconsider drugs for ADHD in childhood, focusing on the newer products.




This article has been cited by other articles:


Home page
 DTBHome page
Clarification: Update on drugs for hyperactivity in childhood
DTB, November 1, 2007; 45(11): 88 - 88.
[Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2007 BMJ Publishing Group Ltd.